This suggests that an overexpression of Tip60 with increased nuclear localization contributes to AR activation in an androgen-independent manner, thus promoting the transition of an androgen-responsive stage to castrate-resistant prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.